文献速递肝病消化道肿瘤与早癌

非酒精性脂肪性肝病的临床前模型

Preclinical models of non-alcoholic fatty liver disease.
PubMed 文献 · J Hepatol · 2017-11-09

非酒精性脂肪性肝病(NAFLD)可表现为非酒精性脂肪肝(NAFL)或非酒精性脂肪性肝炎(NASH),NASH 常伴进展性纤维化,可导致肝硬化和肝细胞癌(HCC)。目前 NASH 尚无获批疗法,主要障碍是缺乏经适当验证能代表人类疾病生物学和结局的临床前模型。本文描述构建 NASH 小鼠模型的最佳实践,综述现有模型及支持其作为人类疾病替代指标的文献,并讨论评估保护性基因的模型数据,希望为解读小鼠模型数据和开发验证更新模型提供指导。

要点

  • NASH 尚无获批疗法,主要障碍是缺乏经适当验证能代表人类疾病生物学和结局的临床前模型。
  • 体外模型不能完全捕捉人类 NASH 的肝脏和肝外环境,大型动物模型昂贵且使用困难。
  • 多数基于遗传或饮食操作的小鼠模型未重现严格定义的脂肪性肝炎,其他模型缺乏针对人类疾病的验证。

核心结论

  • 本文描述构建 NASH 小鼠模型的最佳实践,综述现有模型及支持其作为人类疾病替代指标的文献,并讨论评估保护性基因的模型数据,希望为解读小鼠模型数据和开发验证更新模型提供指导。

研究设计与样本

  • 本文为综述,检索范围未在原文中报告。

主要发现

  • NAFLD 可表现为 NAFL 或 NASH,NASH 常伴进展性纤维化,可导致肝硬化和 HCC。
  • NASH 作为终末期肝病和 HCC 病因呈增加趋势,目前 NASH 尚无获批疗法。
  • 体外模型不能完全捕捉人类 NASH 的肝脏和肝外环境,大型动物模型昂贵且使用困难。
  • 多数基于遗传或饮食操作的小鼠模型未重现严格定义的脂肪性肝炎,即存在肝细胞气球样变伴或不伴 Mallory-Denk 小体,并在大泡性脂肪变性背景下伴炎症。
  • 其他模型缺乏针对人类疾病的验证。

关键数值与推荐

  • 脂肪性肝炎严格定义为存在肝细胞气球样变伴或不伴 Mallory-Denk 小体,并在大泡性脂肪变性背景下伴炎症。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-alcoholic fatty liver disease (NAFLD) can manifest as non-alcoholic fatty liver (NAFL) or non-alcoholic steatohepatitis (NASH). NASH is often associated with progressive fibrosis which can lead to cirrhosis and hepatocellular carcinoma (HCC). NASH is increasing as an aetiology for end-stage liver disease as well as HCC. There are currently no approved therapies for NASH. A major barrier to development of therapeutics for NASH is the lack of preclinical models of disease that are appropriately validated to represent the biology and outcomes of human disease. Many in vitro and animal models have been developed. In vitro models do not fully capture the hepatic and extrahepatic milieu of human NASH and large animal models are expensive and logistically difficult to use. Therefore, there is considerable interest in the development and validation of mouse models for NAFLD, including NASH. Several models based on varying genetic or dietary manipulations have been developed. However, the majority do not recreate steatohepatitis, strictly defined as the presence of hepatocellular ballooning with or without Mallory-Denk bodies, accompanied by inflammation in the presence of macrovesicular steatosis. Others lack validation against human disease. Herein, we describe the best practices in development of mouse models of NASH. We further review existing models and the literature supporting their use as a surrogate for human disease. Finally, data on models to evaluate protective genes are discussed. It is hoped that this review will provide guidance for the interpretation of data derived from mouse models and also for the development and validation of newer models.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Santhekadur PK, Kumar DP, Sanyal AJ, et al. Preclinical models of non-alcoholic fatty liver disease. J Hepatol. 2017. PMID: 29128391. doi:10.1016/j.jhep.2017.10.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。